To determine the extent of neurodegeneration of the visual association cortex, we assessed hyperphosphorylated tau-immunoreactive (HPtau-IR) neurofibrillary tangles in Brodmann Areas 18/19 in nondemented and demented subjects. At least occasional HPtau-IR neurofibrillary tangles were seen in 24% of 59 nondemented subjects with ages at death ranging from 42 to 87 years. The incidence increased to 41% in the 32 nondemented subjects who had HPtau-IR pathology in the hippocampal region. Demented subjects with Braak Stages 0 to III and corticobasal degeneration, frontotemporal lobar degeneration with TAR DNA binding protein 43, vascular cognitive impairment, or dementia with Lewy bodies also had HPtau-IR pathology in Brodmann Areas 18/19. These results support the concept that the occipital association area may have enhanced vulnerability to neurodegeneration. Neuropathologic assessment of these areas is, therefore, recommended, particularly in subjects suspected or known to have had mild cognitive impairment. Occasional HPtau-IR lesions were also seen in the medial temporal gyrus. Thus, the question as to whether scattered HPtau-IR lesions in either temporal or occipital cortex indicate a neurodegenerative disease remains unresolved. Further systematic clinicopathologic studies are needed for an understanding of regional susceptibility to neurodegeneration and the significance of scattered HPtau-IR brain lesions.
INTRODUCTION
In 2006, McKee and colleagues (1) assessed 25 nondemented subjects and reported that 13 (52%) had dense neurofibrillary tangles (NFTs), neuropil threads, and hyperphosphorylated tau-immunoreactive (HPtau-IR) neurites surrounding neuritic plaques not only in the transentorhinal and entorhinal cortices but also in the visual association cortex, particularly in Brodmann Area 19. Based on this finding, the authors concluded that not only the transentorhinal and entorhinal cortices but also the Brodmann Area 19 may display vulnerability to neurodegeneration.
The widely accepted temporo-occipital progression of Alzheimer disease (AD)Yrelated HPtau-IR pathology was described in 1991 by Braak and Braak (2) . In that original study, 83 brains, including 50 clinically unimpaired subjects, were assessed by applying silver techniques. Stage I was reported to be devoid of pathology in the occipital cortex; a few isolated NFTs were seen in some individuals in Stages II to III. The basal isocortical areas were found to be affected, but the occipital cortex was virtually devoid of pathology up to Braak Stage IV in most subjects. Isocortical association areas were affected in all cases in Stage V, and the presence of a distinct dense network of neuropil threads was seen in Layer V of the area striate (Brodmann Area 17) in Stage VI. Thus, the first occipital region to be affected with NFTs was Area 19 followed by Areas 18 and 17 (2) .
Because in both of these studies, NFTs were seen in the visual association areas in subjects defined by the authors as being cognitively intact or clinically unimpaired, the results are not contradictory (1, 2) . It is noteworthy that McKee et al (1) saw NFTs in Brodmann Area 19 in 2 of 9 cognitively intact subjects in Braak Stage I and in 6 of 9 cognitively intact subjects in Braak Stage II. These results suggest that the occipital cortex, particularly Area 19, should be included in the neuropathologic assessment of AD-related HPtau pathology (1) . In the present study, the validity of this suggestion is clarified by analysis of NFTs in the occipital association cortex in a larger cohort of nondemented as well as demented subjects.
MATERIALS AND METHODS

Selection of Subjects
Brain samples were obtained from 77 consecutive autopsies carried out during a 7-month period. The demographics of the patients are given in Table 1 . Many of the subjects had been continuously followed because of a chronic disease. It should be noted that some of the subjects classified as nondemented might have displayed very mild cognitive abnormalities that were not recognized during their lifetime; it is, however, unlikely that the presence of moderate or severe dementia would have been overlooked.
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tissue cassettes (Fig. 1) . One block of the occipital cortex (Fig. 1, block A) represented primary visual cortex including the calcarine region, that is, area striate (Brodmann Area 17) and the adjacent Area 18. Two additional blocks represented basal and apical visual association cortex, Brodmann Areas 18/19 ( Fig. 1, blocks B and C) . A temporal cortex block included middle temporal gyrus (Brodmann Area 21), and 2 specimens were taken from the hippocampus, that is, the anterior portion at the level of uncus and the posterior portion at the level of the lateral geniculate nucleus, as recommended by BrainNet Europe (3).
The specimens were fixed in 10% buffered formalin, embedded in paraffin, and cut into 7-Km-thick sections. Immunohistochemical staining was carried out as previously described (3), applying commercial antibodies to human HPtau at a dilution of 1:500 (Innogenetics, code BR-03, Ghent, Belgium), A-amyloid (clone 6F3D) at a dilution of 1:100 (Dako, Glostrup, Denmark), and >-synuclein (clone KM51) at a dilution of 1:1000 (Novocastra, Newcastle upon Tyne, UK). 
Assessment of HPtau Immunoreactivity in
Other Neuropathologic Assessments
The Braak stage of HPtau pathology was assessed as previously described (3, 4) , whereas the staining was applied on sections from hippocampus, temporal cortex, and occipital cortex. >-SynucleinYimmunoreactive lesions were assessed in sections from medulla, pons, midbrain, basal forebrain, hippocampus, cingulate gyrus, and temporal, parietal and frontal cortices, as recommended by Braak et al (5) . The densities of A-amyloidYIR diffuse and cored plaques were assessed at 100Â magnification in the parietal cortex and scored as none, low, moderate, and high (Fig. 4) . A-Amyloid-IR lesions were assessed in the entire gray matter, and the densities were assessed in the region with maximum involvement. The presence or absence of cerebral amyloid angiopathy was determined in the section of parietal cortex.
Statistical Analysis
SPSS program for Windows (SPSS, Inc, Chicago, IL) was used for the statistical analyses. The Mann-Whitney U test, W 2 test, and Spearman correlation test were used to estimate statistical differences.
RESULTS
The semiquantitative assessment of HPtau-IR NFTs in the occipital cortex of 59 non-demented and 18 demented subjects is given in Table 2 . The subjects are grouped based on their clinical phenotype (non-demented subjects/ demented), Braak stage and the age at death.
HPtau-IR NFTs were seen in Areas 18/19 in 15 (25%) and in Area 17 in 2 (3%) of the 59 non-demented subjects. There were 27 non-demented subjects that did not have any HPtau-IR pathology in the hippocampus (46%, mean age at death 57 T 2 years); in 2 subjects (case 10 and 26) occasional HPtau-IR NFTs were seen in Areas 18/19. Twenty-seven non-demented subjects were in stage IYII (mean age at death, 72 T 2 years), and there were occasional HPtau-IR NFTs seen in Areas 18/19 in 9 subjects (33%). Five of the 59 nondemented subjects were in Braak stages III to IIIYIV (an early stage of IV), HPtau-IR NFTs were seen in Areas 18/19 in 4 subjects, and HPtau-IR NFTs were seen in all investigated occipital areas in 2 subjects. A significant relationship was HPtau-IR NFTs were seen in Area 21 in 20 (34%) of the 59 non-demented subjects. One of the 27 non-demented subjects that did not display any HPtau-IR pathology in the hippocampus (case 18) had occasional HPtau-IR NFT in Area 21. Fourteen of the 27 nondemented subjects in stages IYII had occasional HPtau-IR NFTs in Area 21. Only 4 of these subjects also had concomitant HPtau-IR NFTs in Areas 18/19. All non-demented subjects in Braak Stages III to IIIYIV (an early stage of IV) had occasional to some HPtau-IR NFTs (Scores 1Y2) in Area 21; 4 subjects also had concomitant HPtau-IR NFTs in Areas 18/19.
Ten of the 18 demented subjects (56%) fulfilled the neuropathologic criteria for AD. All of these subjects had HPtau-IR NFTs in Area 21. The predominance of HPtau-IR plaques, neurites, pretangles and tangles varied in Area 21; thus, the scores of HPtau-IR NFTs in these subjects also varied 1 to 4. In 6 of these subjects, HPtau-IR NFTs were seen in all occipital areas; only Areas 18/19 were affected in The slight difference in the incidence of HPtau-IR pathology in Areas 18/19 in nondemented subjects reported here and by McKee et al (1) might be caused by a selection bias. Our cases designated as non-demented were not prospectively studied. They lived at home and were independent, but some of them might have displayed very mild cognitive abnormalities that had not been recognized during their lifetime. By contrast, all subjects in the study by McKee et al (1) were members of the Framingham Heart Study and thus were neuropsychologically assessed. Furthermore, in our material, the age at death of the nondemented subjects in Braak Stages I to IV ranged from 54 to 87 (mean, 74 T 2 years), that is, significantly lower than the subjects aged 60 to 95 years (mean, 82 T 3 years) in the study by McKee et al. Indeed, the numbers of individuals with lesions in the visual cortex in our study increased significantly with increasing age at death. Moreover, the sampling strategy of the occipital blocks differed between the studies. In our study, samples of Area 17 were taken basally and apically from the previous sample including both Areas 18 and 19. Thus, the cortical region of Area 19 on the convexity was not sampled. In addition, the thicknesses of the assessed sections differed, that is, 7 Km here versus 10 Km in those of McKee et al (1) . In both studies, the HPtau-IR NFTs in occipital areas in nondemented subjects were unevenly distributed and had to be sought. This uneven focal distribution might also have contributed to the apparent difference in incidence of HPtau-IR pathology.
Most of our cases had an NFT score from 1 to 2 in Area 18/19 compared with frequent NFT scores of 3 to 4 in Area 19 in McKee et al (1) . This difference in the extent of pathology is probably caused both by the sampling strategy and by the thickness of the section. Area 19 is located on the convexity and was found by McKee et al (1) to be primarily affected, whereas that area was not included in the present study.
Because A-amyloid aggregation is presumed to begin in the neocortex (6), aggregates would be expected in Braak Stages I and II and, possibly, even in cases with involvement only in visual cortex. A-Amyloid aggregation correlated with the involvement of visual cortex in both the present study and in that reported by McKee et al (1) .
Areas 19 to 17 were reported by Braak and Braak (2) to be devoid of pathology in Stage I. That study was carried out on 100-Km-thick sections using the Gallyas silver impregnation technique. Unlike immunohistochemistry, pretangles are not detected with the silver stain. Thus, our finding of 3 nondemented subjects in Braak Stage I displaying occasional HPtau-IR NFTs in Areas 18/19 is probably caused by differences in the detection methodologies used.
A substantial number of nondemented subjects (30%, 9 of 27) in Braak Stages I to II (i.e. pathology restricted to transentorhinal-entorhinal region of hippocampus) also displayed lesions in Areas 18/19. Likewise, there were 5 demented subjects in Braak Stages I to II, and 2 (40%) of them displayed HPtau-IR NFTs in Areas 18/19. Thus, it seems unlikely that the occipital lesions seen in 32% of all of our subjects being in Braak Stages I to II would be only a direct consequence of the HPtau-IR hippocampal lesions. The enhanced vulnerability to neurodegeneration of Area 19 has been previously discussed (1) In only 4 of 27 cases the HPtau-IR NFTs were seen in both of these areas, and all of these subjects were aged (i.e. aged 78Y86 years at death). These results further support the concept of regionally variable susceptibilities to AD-related HPtau pathology.
There were 2 nondemented subjects that displayed HPtau-IR NFTs in the occipital cortex but lacked HPtau pathology in the hippocampus. It is possible that these 2 subjects would have progressed to AD or some primary tauopathy if they had lived longer. In line with this, one of our demented subjects had corticobasal degeneration and lacked HPtau-IR NFTs in the hippocampus but had substantial HPtau-IR pathology in the occipital cortex. Similarly, Tang-Wai et al (17) reported 2 cases with definite corticobasal degeneration displaying Balint syndrome and pathological changes in visual association cortices. Moreover, Bak et al (18) reported visuospatial orientation deficits in corticobasal degeneration.
A new staging strategy of AD-related HPtau-IR pathology was proposed in 2008 (3). This includes the middle temporal gurus but only 1 occipital section taken around the calcarine fissure; thus, it primarily samples Brodmann Area 17 and adjacent Area 18. Our results suggest, however, that sampling of occipital cortex should be expanded to include Brodmann Areas 18 and 19. This extended sampling of the occipital cortex is particularly recommended for studies involving subjects with mild cognitive impairment. This is supported by reports of impaired visual motion processing and abnormal visuospatial orientation not only in AD patients (10Y14, 19, 20) but also in subjects with mild cognitive impairment (21) and in older cognitively intact individuals (20) .
In conclusion, our results support the proposal of McKee et al (1) that visual association cortex is, indeed, altered in cognitively intact and nondemented subjects either lacking or displaying HPtau-IR AD-related pathology restricted only to the entorhinal region. The question as to whether these scattered HPtau-IR NFTs in temporal or occipital neocortex are indeed indicative of a neurodegenerative disease remains unresolved. Our findings emphasize the need for prospective studies to clarify the issues of various regional susceptibilities to HPtau-IR pathology and the clinical and pathophysiological significance of scattered lesions in the brain.
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The authors thank Ewen MacDonald for critical reading of the manuscript. This article reflects only the authors' views and that the Community is not liable for any use that †A-Amyloid-IR diffuse and cored plaques (AA-IR): 0, none; +, low; ++, moderate; +++, high (Fig. 4) . ‡Braak stage of >-synuclein (>S) pathology (5). §0, no NFTs; 1, 1 NFT per 20Â field; 2, 2 to 5 NFTs per 20Â field; 3, 6 to 9 NFTs per 20Â field; 4, 10 or more NFTs per 20Â field. kBlocks are sampled as illustrated in Figure 1 .
AD, Alzheimer disease; CAA, cerebral amyloid angiopathy; CBD, corticobasal degeneration; DLB, dementia with Lewy bodies; F, female; FTLD-TDP, frontotemporal lobar degeneration with TAR DNA binding protein 43; HPtau-IR, hyperphosphorylated tau-immunoreactive; M, male; n.a., not available; NFT, neurofibrillary tangles; VCI, vascular cognitive impairment.
